PKM and colorectal carcinoma: Xing et al. observed that rapamycin-resistant CRC cells DLD-1 displayed an elevated glycolytic rate with the upregulation of glycolytic enzymes, including hexokinase 2, PKM2 and LDHA, and a combination of the mTOR inhibitor Rapamycin and the glycolysis inhibitor 3,4,5,7-tetrahydroxyflavone resulted in synergistically suppressive effects [250].